Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Wino115on Aug 18, 2021 3:39pm
130 Views
Post# 33724851

RE:RE:RE:RE:RE:RE:Kol event

RE:RE:RE:RE:RE:RE:Kol event

It is a great lineup.  One advantage of now hiring Harrison as consultant (aside from what he may bring to trial design) is that he knows all the key players at the key firms developing NASH programs.  Doesn't change my mind, but glad to see THTX management pulling all the levers they possibly can. 

if you ask a question, maybe address it specifically to the person you want the answer from.  I'd love to know Harrison's take on how he sees the pros and cons of the program versus all the others he has led on. 

 


palinc2000 wrote: Qwerty
The main goal of the event is to make you a Believer!!!
You will have a great opportunity to nask the tough questions and you can also if you so wish report here which questions were left out ,,,

 

<< Previous
Bullboard Posts
Next >>